Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Breast 1

Conditions

Multiple Myeloma 3Recurrence 2Disease Progression 1Disease 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × ricolinostat × Plasma cell × Clear all
NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Celgene

Phase 1 Completed
38 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT01323751 2017-04-06

ACY-1215

Celgene

Phase 1/2 Completed
120 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡